Laboratoires Delbert

Since their acquisition of Laboratoires Delbert in 2013 (then a regulatory consulting firm), Marc Childs (a doctor) and Thierry Hoffmann (a pharmacist) have been guided by two objectives: to reintroduce drugs of major therapeutic benefit, considered essential by the WHO, that are affected by supply disruptions (discontinuation, stock shortages, manufacturing difficulties, etc.) and to redirect their production lines back to Europe in order to ensure their availability.

Since then, Laboratoires Delbert has acquired over a dozen drugs at risk of disappearing from the market, in key therapeutic areas including infectiology, oncology and psychiatry. With its employees and the support of clinical, pre‐clinical, formulation, quality and chemical specialists, Laboratoires Delbert gives a new lease of life to the drugs and makes them available to patients again.

To ramp up the pace of further acquisitions of marketing authorisations and give structure to the group, in 2020 the founders decided to open up Laboratoires Delbert’s capital to a pool of investors.

Eager to surround themselves with partners that share both their ambitions for growth and international expansion as well as their commitment to continuity of care, it was only natural that Marc Childs and Thierry Hoffmann chose Sagard NewGen to participate in the funding round.

The transaction also gave the vast majority of employees an opportunity to acquire a stake in the company’s capital.